leflunomide has been researched along with Carcinoma, Medullary in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide (LFN) is a disease-modifying antirheumatic drug approved for the treatment of rheumatoid arthritis, and its active metabolite teriflunomide has been identified as a potential anticancer drug." | 1.39 | Leflunomide suppresses growth in human medullary thyroid cancer cells. ( Alhefdhi, A; Burke, JF; Chen, H; Kunnimalaiyaan, M; Redlich, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhefdhi, A | 1 |
| Burke, JF | 1 |
| Redlich, A | 1 |
| Kunnimalaiyaan, M | 1 |
| Chen, H | 1 |
1 other study available for leflunomide and Carcinoma, Medullary
| Article | Year |
|---|---|
Leflunomide suppresses growth in human medullary thyroid cancer cells.
Topics: Antineoplastic Agents; Antirheumatic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarker | 2013 |